BioXcel Therapeutics Inc
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. I… Read more
BioXcel Therapeutics Inc (BTAI) - Net Assets
Latest net assets as of September 2025: $-88.92 Million USD
Based on the latest financial reports, BioXcel Therapeutics Inc (BTAI) has net assets worth $-88.92 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($44.79 Million) and total liabilities ($133.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-88.92 Million |
| % of Total Assets | -198.52% |
| Annual Growth Rate | N/A |
| 5-Year Change | -145.04% |
| 10-Year Change | N/A |
| Growth Volatility | 299.79 |
BioXcel Therapeutics Inc - Net Assets Trend (2015–2024)
This chart illustrates how BioXcel Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioXcel Therapeutics Inc (2015–2024)
The table below shows the annual net assets of BioXcel Therapeutics Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-93.10 Million | -64.76% |
| 2023-12-31 | $-56.51 Million | -173.60% |
| 2022-12-31 | $76.78 Million | -65.36% |
| 2021-12-31 | $221.67 Million | +7.24% |
| 2020-12-31 | $206.70 Million | +668.53% |
| 2019-12-31 | $26.89 Million | -30.84% |
| 2018-12-31 | $38.89 Million | +4060.18% |
| 2017-12-31 | $-982.00K | -203.09% |
| 2016-12-31 | $-324.00K | -87.28% |
| 2015-12-31 | $-173.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioXcel Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 65019700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $49.00K | % |
| Other Components | $557.05 Million | % |
| Total Equity | $-93.10 Million | 100.00% |
BioXcel Therapeutics Inc Competitors by Market Cap
The table below lists competitors of BioXcel Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Main Street Financial Services Corp
OTCQX:MSWV
|
$33.71 Million |
|
JITF Infralogistics Limited
NSE:JITFINFRA
|
$33.72 Million |
|
Cedergrenska AB
ST:CEDER
|
$33.72 Million |
|
HARMONYCHAIN AS NK -05
F:7EW
|
$33.73 Million |
|
NEXTSOURCE MAT. DL-001
F:1JWA
|
$33.68 Million |
|
Kartal Yenilenebilir Enerji Uretim AS
IS:KARYE
|
$33.67 Million |
|
Eternit S.A
SA:ETER3
|
$33.67 Million |
|
NTG Clarity Networks Inc
PINK:NYWKF
|
$33.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioXcel Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -56,508,000 to -93,101,000, a change of -36,593,000.
- Net loss of 59,599,000 reduced equity.
- New share issuances of 39,688,000 increased equity.
- Other factors decreased equity by 16,682,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-59.60 Million | -64.02% |
| Share Issuances | $39.69 Million | +42.63% |
| Other Changes | $-16.68 Million | -17.92% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares BioXcel Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-0.17 | $1.73 | x |
| 2016-12-31 | $-0.31 | $1.73 | x |
| 2017-12-31 | $-0.95 | $1.73 | x |
| 2018-12-31 | $42.70 | $1.73 | x |
| 2019-12-31 | $26.42 | $1.73 | x |
| 2020-12-31 | $152.52 | $1.73 | x |
| 2021-12-31 | $134.48 | $1.73 | x |
| 2022-12-31 | $43.85 | $1.73 | x |
| 2023-12-31 | $-31.04 | $1.73 | x |
| 2024-12-31 | $-36.73 | $1.73 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioXcel Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2630.14%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-47.35%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-618.70K |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.09 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.44 Million |
| 2018 | -49.55% | 0.00% | 0.00x | 1.12x | $-23.16 Million |
| 2019 | -120.23% | 0.00% | 0.00x | 1.35x | $-35.02 Million |
| 2020 | -39.68% | -337481481.48% | 0.00x | 1.06x | $-102.68 Million |
| 2021 | -48.10% | 0.00% | 0.00x | 1.08x | $-128.80 Million |
| 2022 | -215.90% | -44201.87% | 0.00x | 2.68x | $-173.43 Million |
| 2023 | 0.00% | -12974.86% | 0.02x | 0.00x | $-173.40 Million |
| 2024 | 0.00% | -2630.14% | 0.06x | 0.00x | $-50.29 Million |
Industry Comparison
This section compares BioXcel Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioXcel Therapeutics Inc (BTAI) | $-88.92 Million | 0.00% | N/A | $33.68 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |